## 35th Annual J.P. Morgan Healthcare Conference

**Investor Presentation** 

Nachum "Homi" Shamir President and Chief Executive Officer January, 2017

# complexity simplified.

Luminex.

#### Safe Harbor Statement


Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our partner model and the ability of our partners and installed base to drive future growth; the ability of our technology to enhance productivity and efficiency; our financial position and long-term revenue growth; our ability to integrate our recent acquisition of Nanosphere Inc.; our molecular diagnostic business model, the markets we are targeting, market segmentation, expected growth of such markets, and the ability of our products to address those markets; sales of our products, their technical capabilities, and the anticipated market size and acceptance, demand and regulatory environment and approvals therefor; our direct sales efforts; our system placements; our system and assay product pipeline and anticipated timelines for regulatory approvals and market releases, including for ARIES and Verigene instrumentation and assays; market opportunity for ARIES and Verigene; functionality and benefits of ARIES and Verigene and competitive position; reimbursement trends; our ability to drive growth through investment in R&D and next generation systems and focus on operating leverage and managing operating costs; our long term financial targets; our key steps and strategies for growth; our strategic outlook and growth plan for our business for 2017 and beyond; operational trends, including those related to sales of systems, assays, consumables, and royalty revenues; competitive threats and products offered by other companies; 2017 revenue guidance; our business outlook, financial targets and projections about revenues, cash flow, system shipments, expenses and market conditions, and their anticipated impact on Luminex for 2017 and beyond; and, any statements of the plans, strategies and objectives of management for future operations.

These forward looking statements speak only as of the date hereof and are based on our current beliefs and expectations and are subject to known or unknown risks and uncertainties some of which are beyond our control that could cause actual results or plans to differ materially and adversely from those anticipated in the forward looking statements. Factors that could cause or contribute to such differences are detailed in our annual, quarterly, or other filings with the Securities and Exchange Commission. We undertake no obligation to update these forward looking statements.

Also, certain non-GAAP financial measures as defined by SEC Regulation G, may be covered in this presentation. To the extent that any non-GAAP financial measures are covered, a presentation of and reconciliation to the most directly comparable GAAP financial measures will be included in this presentation may be available on our website at www.luminexcorp.com in accordance with Regulation G.



## Recent Highlights: Strong 2016; Momentum Heading into 2017



# Luminex Corporation: A Life Science and MDx Growth Story

## **Our Goal: Complexity Simplified**

To provide customers in **life science research** and **clinical diagnostics** with **simple to use solutions** that address their most complex needs while **reducing overall cost**.



Large + Growing Base

14,000+ systems cumulative shipped to-date Expanding MDx + IP Portfolio ARIES<sup>®,</sup> Verigene<sup>®,</sup> Project ATLAS 500+ Patents

Razor + Blade Model Strong profitability and cash flow Sample to Answer MDx test revenue growth, pro-forma (2016):

+61%

#### Luminex

#### Luminex Corporation: Business Overview

#### STRATEGIC PARTNERS **Strong Profitability & Cash Flow**



#### **MOLECULAR DIAGNOSTICS** Sample to Answer to Drive Growth Acceleration

Total 2016 proforma MDx test revenue grew 14% over 2015

Significant growth in Verigene-related revenue

2016 MDx Revenue

IVD assay menu in \$122M

100+ Highly Experienced MDx Sales and Support Professionals

Aggressive expansion of **ARIES** and **ATLAS** 

2017 and beyond





FOOTNOTE: Slide does not include "other" revenue generated in 2016

## **Strategic Partners**

**Business Update** 

# complexity simplified.



### **Strategic Partners: Summary**



Luminex.



#### The Partner Business: How it Works

#### Instruments, Consumables & Royalties



Luminex. •


## Molecular Diagnostics: Sample to Answer

**Business Update** 

# complexity simplified.




#### Molecular Diagnostics: Summary







Molecular Diagnostics: Verigene Continues to Grow Rapidly



#### Luminex

© Copyright 2017 Luminex Corporation

SOURCE: MDxI IVD Insights, 2015-1 and 2016-1 -1 and 2016-1

## Molecular Diagnostics: ARIES Progress

#### **CUSTOMER TRACTION**

- Positive customer feedback
- 90+ placements

#### **ARIES M1**

- Right-sized for target customers
- Broadens customer choice


#### **REGULATORY – TEST MENU**

- FDA Cleared: HSV 1&2 , Flu A/B/RSV, GBS
- Submitted to FDA: Bordetella (December)
- Clinical trials: C.Diff, GAS, Norovirus

Group B Strep Now FDA Cleared!



#### Molecular Diagnostics: Customer Sales and Support



#### Molecular Diagnostics: Recent Verigene and ARIES Feedback

After an exhaustive process of evaluating platforms we determined that the Luminex Verigene platform was the perfect fit for our laboratory. The platform is easy to use and flexible in the configuration. As we increase our usage we can easily add more processors to meet the volume increase."

> Riverview Health Laboratory (sub-300 bed community hospital)

I like to refer to Verigene as 'septic care' because I truly believe that this technology offers a premium care for our septic patients."

> Technical Director Molecular diagnostics lab


ARIES is compact, simple to use, easy to expand for additional testing, and the technology yields reliable results. We intend to add to our ARIES-based testing menu as other analytes become available."

> Laboratory Director Molecular diagnostics lab



## Molecular Diagnostics: Project ATLAS

To provide customers in clinical diagnostics with **simple to use solutions** that address their most complex clinical needs.



**Clinical studies:** Current goal is to initiate by end of 2Q17

First assay: High plex enteric panel





#### Molecular Diagnostics: IVD Assay Menu Roadmap

Luminex is rapidly expanding both its molecular targeted and syndromic test menus on a portfolio of Sample to Answer platforms

ARIES

2016

(HSV, Flu A/B/RSV, Group B Strep)

#### Verigene

(Blood Stream Infections, Respiratory, Gastro)

**xTAG** (Respiratory, Gastro, NxTAG Respiratory, CYP2D6, CYP2C19, Cystic Fibrosis)

#### ARIES

201

(HSV, Flu A/B/RSV, Group B Strep, C.Diff, Norovirus, Group A Strep, Bordetella, Others)

#### Verigene

(Blood Stream Infections, Respiratory, Gastro)

#### xTAG

(Respiratory, Gastro, NxTAG Respiratory, CYP2D6, CYP2C19, Cystic Fibrosis) 2018+

ATLAS (Enteric, Respiratory, BCID)

#### ARIES

(HSV, Flu A/B/RSV, Group B Strep, C.Diff, Norovirus, Group A Strep, Bordetella, MRSA, Others)

#### Verigene

(Blood Stream Infections, Respiratory, Gastro)

#### xTAG

(Respiratory, Gastro, NxTAG Respiratory, CYP2D6, CYP2C19, Cystic Fibrosis)

# Molecular Diagnostics: First to Market with S2A Targeted & Syndromic Molecular Tests; Rapid Future Menu Expansion

	MRSA	C Diff	Norovirus	Flu/RSV	GBS	GAS	CT/NG/TV	Respiratory Panel	GI Panel	BCID Panel	Vaginitis Panel
Luminex.											
Cepheid.											
BIO 🕏 FIRE											
GenMark Dx											
Luminex.	© Copyright 2017 Luminex Co	prporation									• 17 •

## **Financial Overview**

# complexity simplified.



### Financial Overview: A Strong Finish to 2016

Revenue \$271M (+14% Y/Y) \$238M 2015 2016

Generated 2016 revenue of \$271M, +14% Y/Y

Acquired Nanosphere – adding a portfolio of infectious disease testing solutions

Commercialized Sample to Answer platform, ARIES. Obtained FDA clearance of ARIES M1 and test menu: HSV 1&2, Flu A/B/RSV, and GBS

Grew partner-related revenue by 13% over 2015

Negotiated \$63M binding commitment from LabCorp through June, 2018

YE15 cash: \$148M; Nanosphere transaction (\$93M); All other items +\$35M; YE16 cash balance at \$90M+





## Financial Overview: Strong 2016; Momentum Carrying into 2017

## \$295M -\$271M \$305M (+14% Y/Y) (+11% Y/Y) \$238M 2015 2016 2017E

Revenue

Partner-related revenue to grow 6 - 8% in 2017


Sample to Answer revenue to be over \$45M in 2017 and \$100M by 2019

Early commercial stage Sample to Answer molecular platforms (e.g. ARIES, Verigene) to temper 2017 corporate gross margins; longer-term gross margins to rise

Nanosphere integration on-track; accretive by YE17



### Financial Overview: Transformation of Our Business



Luminex.

© Copyright 2017 Luminex Corporation

FOOTNOTE: Slide does not include approximately "other" revenue generated in 2016



\* Primarily due to anticipated transition of select Lab Corp testing business

## **Thank You**



complexity simplified.